Ausbil Investment Management Ltd Reduces Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Ausbil Investment Management Ltd decreased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 14.0% in the first quarter, HoldingsChannel.com reports. The fund owned 14,645 shares of the medical instruments supplier’s stock after selling 2,380 shares during the period. Ausbil Investment Management Ltd’s holdings in LeMaitre Vascular were worth $966,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SRS Capital Advisors Inc. raised its holdings in LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 524 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in LeMaitre Vascular in the third quarter worth $38,000. Personal CFO Solutions LLC raised its holdings in LeMaitre Vascular by 6.4% in the fourth quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock worth $316,000 after purchasing an additional 336 shares in the last quarter. KLR Investment Advisors LLC bought a new position in LeMaitre Vascular in the fourth quarter worth $351,000. Finally, Riverwater Partners LLC raised its holdings in LeMaitre Vascular by 2.5% in the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock worth $466,000 after purchasing an additional 198 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT stock traded up $0.36 during trading hours on Friday, reaching $82.64. 3,133 shares of the company traded hands, compared to its average volume of 119,818. The firm has a 50-day moving average price of $76.07 and a 200 day moving average price of $66.36. The company has a market cap of $1.86 billion, a P/E ratio of 54.49, a P/E/G ratio of 2.50 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12-month low of $44.27 and a 12-month high of $84.15.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The firm had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. During the same period last year, the firm earned $0.27 EPS. The company’s revenue was up 13.6% on a year-over-year basis. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.77 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th were given a $0.16 dividend. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.77%. LeMaitre Vascular’s payout ratio is 42.38%.

Insider Activity

In other news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the transaction, the chief executive officer now directly owns 2,079,128 shares in the company, valued at $156,558,338.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the sale, the chief executive officer now directly owns 2,133,428 shares in the company, valued at $161,500,499.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the sale, the chief executive officer now directly owns 2,079,128 shares in the company, valued at $156,558,338.40. The disclosure for this sale can be found here. Insiders have sold 87,431 shares of company stock worth $6,627,520 over the last ninety days. Corporate insiders own 10.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Roth Mkm restated a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a report on Friday, May 31st. Roth Capital upgraded LeMaitre Vascular to a “strong-buy” rating in a report on Friday, May 31st. JMP Securities raised their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and raised their price target for the company from $59.00 to $75.00 in a report on Friday, April 26th. Finally, StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, June 22nd. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $77.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.